Dotinurad

Dotinurad
Clinical data
Trade names	Urece
Other names	FYU-981
ATC code	M04AB06 (WHO) ;
Legal status
Legal status	JP: Rx-only;
Identifiers
	IUPAC name (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone;
CAS Number	1285572-51-1;
PubChem CID	51349053;
DrugBank	DB16145;
ChemSpider	59718651;
UNII	305EB53128;
KEGG	D11071;
ChEMBL	ChEMBL4594446;
Chemical and physical data
Formula	C14H9Cl2NO4S
Molar mass	358.19 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl;
	InChI InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2; Key:VOFLAIHEELWYGO-UHFFFAOYSA-N;

Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia.¹² It was developed by Fuji Yakuhin and approved for use in Japan in 2020,²³ and in China in 2024.⁴ The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.³⁵

Dotinurad is a uricosuric that acts as a selective urate reabsorption inhibitor that has uric acid lowering activity by inhibiting URAT1/SLC22A12 receptor. It and epaminurad are structural analogs of benzbromarone. ⁶⁷

References

Kuriyama S (March 2020). "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology. 24 (Suppl 1): 1–5. doi:10.1007/s10157-019-01811-9. PMC 7066308. PMID 31754883.
"List of Approved Products" (PDF). Pharmaceuticals and Medical Devices Agency.
"Fortress takes on dotinurad in USA and Europe". 5 November 2020. Retrieved 23 June 2021.
""URECE®" (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA". Eisai Co. 11 December 2024. Retrieved 15 May 2026.
"Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". 10 May 2021. Retrieved 23 June 2021.
Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. (October 2019). "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics. 371 (1): 162–170. doi:10.1124/jpet.119.259341. PMID 31371478. S2CID 199382932.{{cite journal}}: CS1 maint: overridden setting (link)
Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T (October 2020). "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters. 11 (10): 2017–2023. doi:10.1021/acsmedchemlett.0c00176. PMC 7549256. PMID 33062187.

[1] Kuriyama S (March 2020). "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology. 24 (Suppl 1): 1–5. doi:10.1007/s10157-019-01811-9. PMC 7066308. PMID 31754883.

[pmda-2] "List of Approved Products" (PDF). Pharmaceuticals and Medical Devices Agency.

[thepharmaletter-3] "Fortress takes on dotinurad in USA and Europe". 5 November 2020. Retrieved 23 June 2021.

[urece_china-4] ""URECE®" (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA". Eisai Co. 11 December 2024. Retrieved 15 May 2026.

[5] "Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". 10 May 2021. Retrieved 23 June 2021.

[6] Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. (October 2019). "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics. 371 (1): 162–170. doi:10.1124/jpet.119.259341. PMID 31371478. S2CID 199382932.{{cite journal}}: CS1 maint: overridden setting (link)

[7] Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T (October 2020). "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters. 11 (10): 2017–2023. doi:10.1021/acsmedchemlett.0c00176. PMC 7549256. PMID 33062187.

1

2

3

4

5

6

7